ClinicalTrials.gg
TerminatedNCT00717522Updated Nov 19, 2019Results posted

Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma

A Phase 2 interventional study of Pomalidomide in Soft Tissue Sarcoma, sponsored by Celgene. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Why this study was terminated
Study enrollment was terminated due to a corporate strategic decision unrelated to patient safety.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 244 under way, 4 of them phase 3. Sarcoma · United States.

Enrollment
709th of 800
7 · median 35
Started
2008
with 27 others
Phase 2
310 of 958
30 open now
Registered
290th of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 709th largest by enrollment of the 800 interventional ones that give a count, is one of 28 that started in 2008, is one of 310 in phase 2, and was the 290th registered.

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to determine the safety and efficacy of single agent CC-4047 (pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are refractory to prior anticancer therapy.

03

Conditions studied

  • Soft Tissue Sarcoma

Browse trials for

Keywords

  • Soft Tissue Sarcoma
  • CC-4047
  • Pomalidomide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be > 18 years of age
  • Must have confirmed soft tissue sarcoma
  • Must have locally recurrent unresectable, or soft tissue sarcoma, and have failed or after a minimum of one and a maximum of 3 prior systemic anticancer therapy regimens
  • Must have measurable or evaluable disease determined as per (RECIST) criteria
  • Must have documented disease progression (PD) determined as per RECIST criteria within 3 months prior to study enrollment
  • Must have (ECOG) performance status score of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females
  • Prior therapy with thalidomide or lenalidomide
  • Prior use of experimental/ drug therapy \< 3 months prior to treatment initiation
  • Prior chemotherapy, biologic or immunotherapy \< 3 weeks prior to treatment initiation
  • Prior radiotherapy \< 3 weeks prior to treatment initiation
  • Prior major surgery \< 3 weeks prior to treatment initiation
  • (ANC) \< 1.5 x 109 cells/L
  • count \< 100 x 109cells/L
  • /serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase/serum glutamic pyruvate transaminase (ALT/SGPT) > 3.0 x (ULN) or > 5.0 x ULN in the presence of demonstrable liver
  • Known active central nervous system (CNS) metastases
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Pomalidomide

    7 mg pomalidomide taken orally once daily (QD) on days 1 through 21 of each 28-day cycle

    Drug: Pomalidomide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, or Discontinuations Due to AEs

    An adverse event (AE) is defined as any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a study subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the study subject's health, including laboratory test values, regardless of etiology. A serious adverse event (SAE) is defined as any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 3.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death. For more details, please see the Adverse Events section of this record.

    Time frame: AEs/SAEs were recorded from informed consent to 30 days post treatment discontinuation visit. Median treatment duration was 49 days (range: 3 to 102 days).

Secondary outcomes

  1. Tumor Response as Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee Guidelines

    Changes in only the longest diameter (LD) of tumor lesions are used in RECIST criteria. Evaluation of target lesions: Complete Response (CR)=Disappearance of all target lesions; Partial Response (PR)=≥30% decrease in sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD; Progressed Disease (PD)=≥20% increase in sum of LD of target lesions taking as reference the smallest sum LD recorded since treatment started or the appearance of ≥1 new lesions; Stable Disease (SD)=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since treatment started. For non-target lesions: CR= Disappearance of all non-target lesions and normalization of tumor marker level; Incomplete Response/SD=Persistence of ≥1 non-target lesions and/or maintenance of tumor marker level above normal limits; PD=Appearance of ≥1 new lesions; unequivocal progression of existing non-target lesions.

    Time frame: Assessed every 8 weeks for the first 8 months and then every 12 weeks thereafter, and at treatment discontinuation. Median treatment duration was 49 days (range: 3 to 102 days).

07

Results

Posted Apr 16, 2013

Participant flow

Participant flow — Overall Study
MilestonePomalidomide
Started7
Completed0
Not completed7
Withdrew: Disease progression5
Withdrew: Adverse event1
Withdrew: Death1

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, or Discontinuations Due to AEs

An adverse event (AE) is defined as any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a study subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the study subject's health, including laboratory test values, regardless of etiology. A serious adverse event (SAE) is defined as any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 3.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death. For more details, please see the Adverse Events section of this record.

Time frame:
AEs/SAEs were recorded from informed consent to 30 days post treatment discontinuation visit. Median treatment duration was 49 days (range: 3 to 102 days).
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, or Discontinuations Due to AEs
participantsPomalidomide
≥1 AE7
≥1 AE suspected to be related to study drug6
≥1 Grade 3 AE4
≥1 Grade 4 AE1
≥1 SAE3
≥1 SAE suspected to be related to study drug1
Death4
Death within 30 days of last dose of study drug1
Discontinuation due to AE2
Dose reduction and interruption due to AE1
SecondaryTumor Response as Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee Guidelines

Changes in only the longest diameter (LD) of tumor lesions are used in RECIST criteria. Evaluation of target lesions: Complete Response (CR)=Disappearance of all target lesions; Partial Response (PR)=≥30% decrease in sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD; Progressed Disease (PD)=≥20% increase in sum of LD of target lesions taking as reference the smallest sum LD recorded since treatment started or the appearance of ≥1 new lesions; Stable Disease (SD)=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since treatment started. For non-target lesions: CR= Disappearance of all non-target lesions and normalization of tumor marker level; Incomplete Response/SD=Persistence of ≥1 non-target lesions and/or maintenance of tumor marker level above normal limits; PD=Appearance of ≥1 new lesions; unequivocal progression of existing non-target lesions.

Time frame:
Assessed every 8 weeks for the first 8 months and then every 12 weeks thereafter, and at treatment discontinuation. Median treatment duration was 49 days (range: 3 to 102 days).

No measurements were reported for this outcome.

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first treatment of the study medication and within 30 days after the last dose. Median treatment duration was 49 days (range: 3 to 102 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pomalidomide—3/7 (42.9%)7/7 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPomalidomide
Cancer PainNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/7
Sarcoma MetastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/7
AnaemiaBlood and lymphatic system disorders1/7
Febrile NeutropeniaBlood and lymphatic system disorders1/7
LeukopeniaBlood and lymphatic system disorders1/7
NeutropeniaBlood and lymphatic system disorders1/7
TachycardiaCardiac disorders1/7
DysphagiaGastrointestinal disorders1/7
MalnutritionMetabolism and nutrition disorders1/7
Muscle SpasmsMusculoskeletal and connective tissue disorders1/7
Most frequent other events
Showing 10 of 60
Most frequent other events
EventPomalidomide
NauseaGastrointestinal disorders3/7
AnaemiaBlood and lymphatic system disorders3/7
NeutropeniaBlood and lymphatic system disorders3/7
ConstipationGastrointestinal disorders2/7
Dry mouthGastrointestinal disorders2/7
FatigueGeneral disorders2/7
ThrombocytopeniaBlood and lymphatic system disorders2/7
Pleural effusionRespiratory, thoracic and mediastinal disorders2/7
HypoalbuminaemiaMetabolism and nutrition disorders2/7
HypocalcaemiaMetabolism and nutrition disorders2/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pomalidomide
Mean58.9 ± 13.52
Sex: Female, Male
Sex: Female, Male(Participants)Pomalidomide
Female3
Male4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pomalidomide
White7
Non-white0
08

Study locations

3 sites
  • Sarcoma Oncology Center
    Santa Monica, California 90403, United States
  • Kootenai Cancer Center
    Coeur d'Alene, Idaho 83814, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68114, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2008 to primary completion in Jan 2009, 5 months.

Results were first posted in Apr 2013, 4 years 3 months after primary completion. A results delay was requested in Oct 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2008
First posted
Jul 17, 2008
StartActual
Aug 1, 2008
Primary completionActual
Jan 1, 2009
CompletionActual
Jan 1, 2009
Results delay requested
Oct 8, 2012
Results first posted
Apr 16, 2013
Last update
Nov 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00717522
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jul 17, 2008
Start date
Aug 1, 2008
Primary completion
Jan 1, 2009
Completion
Jan 1, 2009
Results posted
Apr 16, 2013
Last update
Nov 19, 2019

Study contacts

Abderrahim Fandi, MD
study director · Celgene

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pomalidomide

Start the discussion